Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2008
10/30/2008WO2008103471A3 Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
10/30/2008WO2008100498A3 Treatment of inflammatory diseases using placental stem cells
10/30/2008WO2008098139A3 Axl tyrosine kinase inhibitors and methods of making and using the same
10/30/2008WO2008097817A3 Multivariable antigens complexed with targeting humanized monoclonal antibody
10/30/2008WO2008093249A3 Obligate heterodimer meganucleases and uses thereof
10/30/2008WO2008089883A3 Tri-demethylation-capable protein complex, method of its preparation and its use
10/30/2008WO2008088884A3 Enhanced cell-free synthesis of active proteins containing disulfide bonds
10/30/2008WO2008088583A3 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
10/30/2008WO2008084237A3 Stabilization of aqueous compositions of proteins with displacement buffers
10/30/2008WO2008079326A3 Methods for using and identifying modulators of delta-like 4
10/30/2008WO2008078177A3 Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
10/30/2008WO2008075206A3 Cell-matrix microspheres, methods for preparation and applications
10/30/2008WO2008074329A3 Modulation of activity of proneurotrophins
10/30/2008WO2008073312A3 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
10/30/2008WO2008070049A8 Peptide and treatment for hiv-1 infection
10/30/2008WO2008067480A3 Myostatin inhibition for enhancing muscle and/or improving muscle function
10/30/2008WO2008063369A3 Biomarkers for neurological conditions
10/30/2008WO2008060485A9 Diagnosing, monitoring and treating inflammation
10/30/2008WO2008057709A3 Sol-gel materials for cellular modulation
10/30/2008WO2008057208A3 Hcv ns3 protease inhibitors
10/30/2008WO2008057162A3 Native (telopeptide) placental collagen compositions
10/30/2008WO2008051496A3 Use of il-1 antagonists to treat gout and pseudogout
10/30/2008WO2008046860A3 Bioavailable combinations for hcv treatment
10/30/2008WO2008031091A3 A surface-based ammonium ion sensor: an electrode derivatized with a self-assembled monolayer
10/30/2008WO2008022784A3 Long-lasting absorption of flavonoids
10/30/2008WO2008022253A3 An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
10/30/2008WO2008022006A3 Arylalkoxyl hepatitis c virus protease inhibitors
10/30/2008WO2008019303A3 Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
10/30/2008WO2008016490A3 Modified two-component gelation systems for the treatment of post-myocardial infarction
10/30/2008WO2008009004A3 Reagents for the detection of protein phosphorylation in signaling pathways
10/30/2008WO2008008526A3 Treating obesity and gastro-intestinal disorders using botulinum toxin
10/30/2008WO2007134241A3 Nasal delivery of therapeutic agents using tight junction agonists
10/30/2008WO2007130113A3 Parathyroid hormone analogues and methods of use
10/30/2008WO2007127683A3 Administration of agonist-antagonist in opioid-dependent patients
10/30/2008WO2007127200A3 Antibiotic compounds
10/30/2008WO2007125210A3 Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
10/30/2008WO2007100782A8 Biomarkers for amyotrophic lateral sclerosis and methods using the same
10/30/2008WO2007092598A3 Novel neurological function of mpkci
10/30/2008WO2007076319A3 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
10/30/2008WO2007074191A3 Synergistic effect between a cyanogenic system and another oxidative inducer for the treatment of tumours
10/30/2008WO2007008859A3 Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue
10/30/2008WO2006124627A3 Methods of treating conditions involving neuronal degeneration
10/30/2008WO2006073950A3 Nanoparticles for protein drug delivery
10/30/2008WO2004112717A3 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
10/30/2008US20080271167 for treatment of viral infection and nervous systtem disorders
10/30/2008US20080269666 Microneedles and Methods for Microinfusion
10/30/2008US20080269585 System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
10/30/2008US20080269472 Expression vector comprising nucleotide sequences coding UP50 protein and endothelial growth factor for use in treatment of vascular disorders; regenerative medicine; tissue engineering and repair
10/30/2008US20080269462 Peptide inhibitors of HIV entry
10/30/2008US20080269344 respiratory diseases such as asthma, chronic obstructive pulmonary disease, bronchitis; useful in the treatment of nervous system injury and premature labor; 1-{2-[N-2-(4-hydroxy-3-formylaminophenyl)-2-(RS) hydroxyethyl]aminoethyl}-4-[N-(2-phenyl-2-(RS)-hydroxyethyl)amino]phenyl; milveterol
10/30/2008US20080269234 Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents
10/30/2008US20080269165 Use of sulfated glycosaminoglycans for establishing effective labor in women
10/30/2008US20080269160 Immune response against antigen in vivo; gold particle bombardment, nucleotide sequence encoding chimeric protein, antigen in one nucleic acid in an adenoviral vector; chimeric protein is myristoylation membrane targeting region; AP1903 ligand-binding region; CD40 cytoplasmic polypeptide region
10/30/2008US20080269147 Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response; autoimmune disease; tumor-associated gene
10/30/2008US20080269143 Dual delta and mu opioid receptor antagonist; 3,6-Bis(Boc-Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
10/30/2008US20080269142 Endogenous thiadiazabicyclo glutathione-adduct
10/30/2008US20080269141 Peptide Substance Restoring Myocardium Function
10/30/2008US20080269140 Conformationally Constrained Smac Mimetics and the Uses Thereof
10/30/2008US20080269139 FGF-5 Supported and Binding Peptides
10/30/2008US20080269138 Selectively bind DNA and entering nucleus of cells; for modulating gene expression in cells
10/30/2008US20080269137 Compositions and methods for modulating the immune system
10/30/2008US20080269136 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
10/30/2008US20080269135 Method of treatment for early stage cancer
10/30/2008US20080269134 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
10/30/2008US20080269133 Compositions and methods of use of epb1, and erbb3 binding protein
10/30/2008US20080269132 Use of low temperature and/or low ph in cell culture
10/30/2008US20080269131 Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis
10/30/2008US20080269130 Methods and compositions for treating hypoglycemic disorders
10/30/2008US20080269129 Polypeptide and dna thereof useful as a neovascular marker
10/30/2008US20080269128 Albumin Fusion Proteins
10/30/2008US20080269127 Albumin Fusion Proteins
10/30/2008US20080269126 Albumin Fusion Proteins
10/30/2008US20080269125 Albumin Fusion Proteins
10/30/2008US20080269124 Stabilizer Molecule-Enriched Albumin Solution
10/30/2008US20080269123 Using modulator of tumor necrosis factor (TNF) pathway such as infliximab, simvastatin; drug screening
10/30/2008US20080269122 Monoclonal antibody fusion comprising cathelicidin which targets microorganiams for destruction; for use in health care, veterinary medicine and food processing
10/30/2008US20080269121 Methods and Compositions Involving A1c Subunit of L-Type Calcium Channels in Smooth Muscle Cells
10/30/2008US20080269120 Biodrugs comprising polypeptides and carriers comprising bioadhesives such as fibrin, for treatment of vision defects; chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating cancer
10/30/2008US20080269119 Ophthalmic Device and Related Methods and Compositions
10/30/2008US20080269118 Identifying molecule suitable for treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, by determining whether candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which Gpr100 polypeptide comprises specific amino acid sequence
10/30/2008US20080269117 Regulating plasma glucose concentration and/or increasing insulin sensitivity in mammal by administering nutritional or pharmaceutical composition containing protein fraction comprising 10.8 wt % aspartate equivalents, where part is provided by aspartate source containing 12.0 wt % aspartate equivalents
10/30/2008US20080269116 Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
10/30/2008US20080269115 Immunogenic Sars Domain
10/30/2008US20080269114 Y4 Selective Receptor Agonists For Thereapeutic Interventions
10/30/2008US20080269113 P53 binding t cell receptor molecules
10/30/2008US20080269112 Antineoplastic Agents Targeted via Glut Transporters
10/30/2008US20080269111 Administering to a subject an apolipoprotein-sphingomyelin complex comprising an apolipoprotein and the lipid sphingomyelin in an amount effective to achieve a serum level of free or complexed apolipoprotein in the range of 30 mg/dL to 300 mg/dL after administration; treatment of cardiovascular disease
10/30/2008US20080269110 Non-basic melanin concentrating hormone receptor-1 antagonists
10/30/2008US20080269109 System and method of resuscitation of a mammal
10/30/2008US20080269108 Crystalline forms of the Di-Sodium Salt of N-(5-Chlorosalicyloyl)-8-Aminocaprylic Acid
10/30/2008US20080269107 Treatment of mammalian cancers by the administration of HOXB4 protein and/or the overexpression of HOXB4 nucleotide sequence in order to induce apoptosis or otherwise decrease the survival of the target cancer cells
10/30/2008US20080269106 Methods and Compositions for Diagnosis and Treatment of Disorders Involving Macrophages
10/30/2008US20080269105 Useful delivery of drugs can be obtained through the association of drugs with certain polymers which are referred to as CYSC polymers (crystallizable side chain polymers)
10/30/2008US20080269104 Methods For Enhancing the Quality of Life of a Growing Animal
10/30/2008US20080269103 Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease
10/30/2008US20080268532 Dipeptidyl peptidases
10/30/2008US20080268499 Nucleotide sequences coding hormone recptors for use in identifying modulaors of insect propagation; biological pest control; insecticides
10/30/2008US20080268489 Therapeutic polypeptide for use in treatment of heart, hypothermic and cardiovascular disorders
10/30/2008US20080268484 Using thrombin-antithrombin III complex as tool in identifying modulators of glypican-3 expression; treating arteriosclerosis
10/30/2008US20080268424 Glut-1 as a Receptor for Htlv Envelopes and its Uses
1 ... 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 ... 3163